Aarti Pharma Q1 FY27 Earnings Call — Analysis (NSE: AARTIPHARM)

Aarti Pharmalabs Q1FY27 revenue jumps 42% YoY to ₹535 Cr on record Xanthine sales and capacity ramp-up, CDMO growth guidance maintained at 40-50% for FY27.

17 Aug 2026 · Analysis by Alpha Inflection

Result quality: strong — Margin expansion. Management sentiment: optimistic.

The take

Q1FY27 Revenue ₹535 Cr ( +42% YoY ) . New guidance — FY27 cdmo segment revenue growth in… 40% to 50% . New story: Xanthine global dominance via capacity .

Results

Revenue ₹535 Cr +42% YoY; EBITDA ₹133 Cr +40% YoY; PAT ₹71 Cr +49% YoY.

Financial highlights

Guidance

FY27 EBITDA margin guided at 22-25%, CDMO revenue growth 40-50%, and Xanthine full-year revenue expected in ₹900-1,000 Cr range despite normalising prices.

What management committed to

• Xanthine derivatives enhanced capacity will reach 80% plus capacity utilisation by FY28. — 80% plus, FY28
• Aarti Pharmalabs is aiming for 20% to 25% global market share in Xanthine derivatives with the enhanced capacity in the next 2 years' time. — 20% to 25%, FY29
• CDMO/CMO segment revenue will grow 40% to 50% year-on-year in FY27. — 40% to 50%, FY27
• CDMO/CMO revenue in FY27 will be skewed towards the second half of the financial year. — FY27
• Atali Block 2 dedicated CDMO block (400+ kL) groundbreaking is expected in Q3FY27 and completion timeline is 12 to 15 months. — FY28
• CDMO/CMO segment will achieve annual revenue of ₹1,000 Cr in a few years (FY29-30). — ₹1,000 Cr, FY30
• API and Intermediate segment FY27 revenue will not cross the FY25 level (~₹780 Cr) but will be nearly there. — nearly there (not cross ₹780 Cr), FY27
• Xanthine derivatives full-year FY27 revenue in the range of ₹900 Cr to ₹1,000 Cr. — ₹900 Cr to ₹1,000 Cr, FY27
• For the combined CDMO capex (Atali Block 1 ₹450 Cr + Block 2 ₹149 Cr), asset turnover is expected around 1x when fully ramped. — around 1x, when fully ramped (implied)
• Xanthine production capacity will reach 9,500 metric tonnes in the next couple of years. — 9,500 tonnes, FY29

Key themes

Xanthine capacity ramp and CDMO capex commitment

How the narrative shifted

• Xanthine global dominance via capacity: Aarti is aggressively scaling Xanthine to become the second-largest global producer, targeting 20-25% market share, leveraging structural cost advantages and China's policy shifts.
• CDMO commercial ramp-up: CDMO growth is backed by dedicated capex, 37 commercial projects, and a clear path to ₹1,000 Cr revenue, with a focus on manufacturing scale-up and process expertise.
• API margin recovery through cost initiatives: API segment faces pricing pressure but the company is undertaking process intensification, debottlenecking and cost reduction to restore profitability and prepare for future launches.
• Macro: Xanthine raw material volatility: Temporary raw material spikes from the Middle East crisis boosted Q1 Xanthine margins; normalisation expected, but structural China changes (rebate removal) provide a new floor.
• Capex cycle and pre-op absorption: Multiple greenfield/brownfield projects are moving from execution to commercialisation; near-term pre-op costs will be absorbed by volume ramp-up without significant P&L disruption.
• China competitive dynamics shift: China's involution policy (rebate removal) and production quota tightening are structurally improving the competitive landscape for Indian Xanthine producers.

Operational commentary

• Xanthine: L99 brownfield capacity commercialised, trial production started; capacity increased from 6,000 MT to 9,500 MT, targeting 80%+ utilisation by FY28; aiming for 20-25% global market share in 2 years.
• Steroid block debottlenecking completed at USFDA-approved Unit 4 Tarapur, adding 33% capacity; now fully utilised after 1.5-month Q1 shutdown.
• Atali Block 1 (440 kL reactor capacity) fully operational in Q2FY27; Phase 2 smaller block completing in Q2; pre-operative expenses start hitting in H2.
• Atali Block 2 capex announced: ₹149 Cr for 400+ kL dedicated CDMO block, groundbreaking Q3FY27, completion 12-15 months; designed for 3-4 specific CDMO projects with visibility.
• CDMO/CMO: 22 customers, 57 active projects (37 commercial, 20 developmental); growth guidance 40-50% YoY, H2-heavy; aspirational revenue target ₹1,000 Cr in FY29-30.
• API & Intermediates: continued pricing pressure; launched special project for process intensification and cost reduction; anticancer block debottlenecking planned for future launches; capacity sufficient for ₹1,000 Cr+ ambition.
• R&D: over 250 scientists across 3 centres; new capabilities in peptides and oligonucleotides; CXO-level hires (CSO, CTO, COO) strengthening tech leadership.

Analyst Q&A

• Q. Xanthine global market share target with enhanced capacity?

  We are aiming towards 20% to 25% global market share with the enhanced capacity in the next 2 years' time.

• Q. What is the normalised through-the-cycle EBITDA margin range for Xanthine at full utilisation?

  We are not normally guiding on the EBITDA percentage for Xanthine because of raw material pass-through. At company level we see 20-25% EBITDA.

• Q. Volume growth versus realisation growth in Xanthine Q1?

  Volume growth was about 25% over last year; the value number we will have to check and get back.

• Q. Will CDMO revenues continue to remain H2-heavy this year?

  Yes, for the current year this will be H2 heavy, and we are confident of 40-50% growth.

• Q. How has the complexity and value of the CDMO segment changed, and what are the structural gross margins?

  We have moved from ISO to GMP supply, now doing API for clinical batches. CDMO commercial gross margin is around 60-65%, not 75-85% because we specialise in manufacturing scale-up, not early-stage research.

• Q. Is the dedicated CDMO block for one customer/molecule, and is there visibility of ₹200-250 Cr per molecule projects?

  Block will be used for 3-4 projects for multiple customers. We have visibility but I would not like to comment on numbers.

View source

Research and educational content only. Not investment advice.